IGC Pharma (IGC) Total Liabilities (2011 - 2026)

IGC Pharma (IGC) has 16 years of Total Liabilities data on file, last reported at $3.1 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $3.1 million, up 26.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (up 26.77% YoY), and the FY2026 annual result was $3.1 million, up 26.77% from the prior year.
• Total Liabilities advanced to $3.1 million in Q1 2026 per IGC's latest filing, from $2.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $3.1 million in Q1 2026 and troughed at $1.7 million in Q3 2025.
• A 5-year average of $2.4 million and a median of $2.4 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities surged 32.75% in 2023, then tumbled 44.82% in 2025.
• A 5-year view of Total Liabilities shows it stood at $1.8 million in 2022, then gained by 25.84% to $2.2 million in 2023, then rose by 27.79% to $2.8 million in 2024, then slipped by 18.8% to $2.3 million in 2025, then jumped by 33.86% to $3.1 million in 2026.
• Business Quant data shows IGC's Total Liabilities at $3.1 million in Q1 2026, $2.3 million in Q4 2025, and $1.7 million in Q3 2025.